TNF and ankylosing spondylitis: A range of them are currently licensed as TNFα-blocking agents and are being used in the management of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis and Crohn's disease, with a varying degree of success [36]–[38].